Drug Development Services Global Market Report 2026

Drug development services refer to specialized services that support the discovery, testing, regulatory approval, and commercialization of new pharmaceutical and biotechnology products. Its purpose is to accelerate the development of safe and effective drugs, reduce time-to-market, and ensure compliance with regulatory standards.

The primary types of drug development services include drug metabolism and pharmacokinetics, biological services, and medicinal chemistry. Drug metabolism and pharmacokinetics involve the study of how drugs are absorbed, distributed, metabolized, and excreted in the body, providing essential data for safe and effective drug development. These services support processes such as candidate validation, lead optimization, hit-to-lead identification, target validation, and target selection. They are applied across drug types including biologics, infectious disease diagnostics, and small molecules. The therapeutic areas covered include cardiovascular disease, digestive system disease, immune system and infectious diseases, neurology, oncology, and other therapeutic areas, and they are used by end users such as pharmaceutical companies, biotechnology companies, contract research organizations, and academic and research institutes.

Tariffs have influenced the drug development services market by increasing the cost of imported laboratory equipment, reagents, and specialized chemicals essential for preclinical and clinical testing. The impact is most pronounced on drug metabolism, medicinal chemistry, and biological services segments, particularly in regions like North America and Europe that rely on imported materials. Some domestic service providers benefit from the shift toward local sourcing, creating opportunities for regional CROs and research institutes to expand service offerings.

The drug development services market size has grown rapidly in recent years. It will grow from $28.09 billion in 2025 to $31.5 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growth in r&d investments by pharma companies, increase in outsourcing of drug development services, rising prevalence of chronic and infectious diseases, stricter regulatory compliance requirements, advancements in molecular biology and in vitro testing.

The drug development services market size is expected to see rapid growth in the next few years. It will grow to $50.26 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to adoption of ai and machine learning in drug discovery, expansion of biologics and personalized medicine pipelines, increasing demand for contract research organizations, integration of cloud-based clinical data management, growth in emerging markets for drug development services. Major trends in the forecast period include preclinical research expansion, regulatory affairs optimization, pharmacovigilance enhancement, clinical data management services growth, quality assurance and compliance services strengthening.

The growing emphasis on precision and personalized medicine is expected to drive the growth of the drug development services market going forward. Precision and personalized medicine refers to a healthcare approach that customizes medical treatments and interventions based on patients' genetic profiles, clinical characteristics, and specific disease conditions. The focus on precision and personalized medicine is increasing due to advancements in genomic technologies that allow more accurate diagnosis and targeted treatment selection. Drug development services enable precision and personalized medicine by facilitating the design, testing, and validation of targeted therapies tailored to specific genetic, molecular, and patient-related disease factors. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared with six approvals in 2022. Therefore, the growing emphasis on precision and personalized medicine is driving the growth of the drug development services market.

Leading companies in the drug development services market are focusing on developing innovative solutions, such as science-driven formulation acceleration platforms, to streamline early-stage drug formulation and reduce time-to-market for complex drug candidates. Science-driven formulation acceleration platforms are integrated development programs that apply targeted technologies and structured protocols to rapidly optimize drug formulations and advance them toward clinical testing. For example, in May 2025, Aenova Group GmbH, a Germany-based pharmaceutical company, launched the Aenovation program to accelerate the early development of pharmaceutical formulations, especially for poorly soluble compounds that are challenging to progress through the pipeline. The program uses a three-step approach, including comprehensive API profiling and developability classification, rapid formulation and prototype selection using solubility enhancement technologies, and seamless transfer to GMP lab and pilot-scale manufacturing to deliver right-first-time results and materials for first-in-human trials more quickly. By addressing critical bioavailability challenges and enabling efficient formulation strategies, the Aenovation program helps pharma innovators, including biotech start-ups, bring innovative therapies closer to clinical phases with greater speed and resource efficiency.

In September 2025, Symeres B.V., a Netherlands-based pharmaceutical company, acquired DGr Pharma for an undisclosed amount. Through this acquisition, Symeres expanded its early-phase drug development services and regulatory expertise to offer a more integrated end-to-end development platform for biopharmaceutical clients. DGr Pharma is a Netherlands-based firm providing consulting and operational support for early-stage pharmaceutical development.

Major companies operating in the drug development services market are IQVIA Holdings Inc., Labcorp Drug Development, Lonza Group AG, SGS Life Sciences, ICON plc, Eurofins Scientific SE, PPD Inc., Syneos Health Inc., WuXi AppTec Co. Ltd., Catalent Inc., Charles River Laboratories International Inc., Parexel International Corporation, Samsung Biologics Co. Ltd., Medpace Holdings Inc., PRA Health Sciences Inc., Fujifilm Diosynth Biotechnologies, Recipharm AB, PCI Pharma Services Inc., Almac Group Limited, Evotec SE, Aenova Group GmbH, Rentschler Biopharma SE, BioReliance Corporation, Covance SE

North America was the largest region in the drug development services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug development services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug development services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug development services market includes revenues earned by entities through the preclinical research services, in vitro testing services, toxicology and safety assessment, clinical data management, biostatistics services, regulatory affairs and submission support, pharmacovigilance services, and quality assurance and compliance services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The drug development services market research report is one of a series of new reports from The Business Research Company that provides drug development services market statistics, including drug development services industry global market size, regional shares, competitors with a drug development services market share, detailed drug development services market segments, market trends and opportunities, and any further data you may need to thrive in the drug development services industry. This drug development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug Development Services Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drug development services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug development services ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug development services market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Drug Metabolism And Pharmacokinetics; Biological Services; Medicinal Chemistry
• 2) By Process: Candidate Validation; Lead Optimization; Hit To Lead Identification; Target Validation; Target Selection
• 3) By Drug: Biologics; Infectious Disease Diagnostics; Small Molecules
• 4) By Therapeutic Area: Cardiovascular Disease; Digestive System Disease; Immune System And Infectious Disease; Neurology; Oncology; Other Therapeutic Areas
• 5) By End User: Pharmaceutical Companies; Biotechnology Companies; Contract Research Organizations; Academic And Research Institutes
• Subsegments:
• 1) By Drug Metabolism And Pharmacokinetics: Absorption Studies; Distribution Studies; Metabolism Studies; Excretion Studies; Bioavailability Assessment; Drug Drug Interaction Studies
• 2) By Biological Services: Cell Based Assays; Molecular Biology Services; Protein Expression And Purification; Biomarker Discovery; In Vitro Pharmacology
• 3) By Medicinal Chemistry: Compound Design And Synthesis; Structure Activity Relationship Studies; Lead Optimization Chemistry; Chemical Library Development; Process Chemistry Development
• Companies Mentioned: IQVIA Holdings Inc.; Labcorp Drug Development; Lonza Group AG; SGS Life Sciences; ICON plc; Eurofins Scientific SE; PPD Inc.; Syneos Health Inc.; WuXi AppTec Co. Ltd.; Catalent Inc.; Charles River Laboratories International Inc.; Parexel International Corporation; Samsung Biologics Co. Ltd.; Medpace Holdings Inc.; PRA Health Sciences Inc.; Fujifilm Diosynth Biotechnologies; Recipharm AB; PCI Pharma Services Inc.; Almac Group Limited; Evotec SE; Aenova Group GmbH; Rentschler Biopharma SE; BioReliance Corporation; Covance SE
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.